A few days ago, Sirnaomics, Inc. announced that it has completed D round financing at $105 million (about RMB 730 million). Sirnaomics, Inc. is a biomedical R&D enterprise dedicated to the development of targeted drugs through independent innovation and application of Ribonucleic Acid (RNA) interference technology. The company is the first company to conduct clinical research on RNA innovative drugs simultaneously in China and the United States. It is also the undertaking unit of major new drug creation projects in the 11th, 12th and 13th Five-Year Plans. In the field of miRNA interference drug development, Sirnaomics, Inc. is in a leading position in China and is also a global leader. CR Healthcare Fund has completed the investment in the last round.
After completing this round of financing, Sirnaomics, Inc. will further advance the clinical trials of its product lines, including a variety of therapeutic products for cancer, fibrosis, metabolic diseases and viral infections, as well as the combination with immune checkpoint inhibitors; further expand its delivery system platform, including siRNA-chemo drug conjugate technology, small peptide galactosamine conjugate (PdoV-GalNAc) technology, and improve aerosol drug delivery devices to accelerate its clinical progress and commercialization of the products under development.
About CR Healthcare Fund
CR Healthcare Fund focuses on investing in innovative products, technologies and services in the field of life sciences. The fund team has invested in China’s two leading companies in the field of small interfering RNA, Sirnaomics, Inc. and Suzhou Ribo Life Science Co.,Ltd, also made layouts in the fields of Car-T, antibodies, respiratory tract drugs and oncolytic viruses. Relying on the powerful industry platform of shareholders, CR Healthcare Fund is committed to creating value for investors and enabling Chinese people to use global innovative life science products and technologies faster.
About Small Interfering RNA Drugs
Small interfering RNA drugs, also known as RNA interference (RNAi) drugs, were rated as one of the top ten scientific advances in 2001 by the American Journal of Science, and the first of the top ten scientific progress in 2002. American scientists Dr. Andrew Fire and Dr. Craig Mello, who discovered the RNAi mechanism, jointly won the Nobel Prize in Physiology in 2006. In 2018, Onpattro (Patisiran) developed by Alnylam Pharmaceuticals, a global leader in this field, became the first miRNA drug approved by the FDA, which aroused the attention of the capital market in this field. In 2019, it was named Technology of The Year in the field of life science and technology. In April 2020, Blackstone Life Sciences reached a strategic partnership with Alnylam to provide up to US$2 billion in funding Alnylam to promote the development of innovative technologies and accelerate the commercialization process, which also set the highest record of private equity for biotech companies. Currently, Alnylam's market value has exceeded US$15 billion. Although other leading companies in this field are still in the R&D stage, they have also been recognized by the capital market, including Arrowhead with a market value of US$6 billion and Dicerna with a market value of US$1.5 billion.
